UNSPSC 51142528: Ifenprodil

This classification denotes a platelet aggregation inhibitor, antiparkinson agent, and anticonvulsant with the molecular formula 2C21H27NO2.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 89CTB4XUF7, chemically known as 4-benzyl-1-(beta,4-dihydroxy-alpha-methylphenethyl)piperidinium hydrogen tartrate but generally known as ifenprodil tartrate, which bears US NIH Compound Identifier 134832.

UNSPSC 51142528 Ifenprodil is a Commodity code that represents pharmaceutical products, though recent state and local solicitation activity under this code does not align with the nominal category name. The single recent opportunity on record—Seminole County, Florida's IFB 60459723LAS—solicits naloxone and drug deactivation systems for community health initiatives, not ifenprodil specifically. State and local governments use codes within this pharmaceutical family to procure medications and medical supplies for public health departments, emergency response programs, and community health facilities. Issuing bodies include county health departments and special-purpose districts managing emergency medical services and substance-abuse intervention programs.

Seminole County, Florida represents the only recent posted opportunity under this code. The county issued an IFB on June 30, 2026 (with a due date of July 26, 2023 in the source—a date inconsistency in the posting record itself) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to the Seminole County Community Health Building in Sanford. Bidders must include shipping and delivery costs in their proposals, maintain drug-free workplace certification and E-Verify compliance, and carry workers' compensation and commercial general liability insurance. The contract carries an initial two-year term with a one-year renewal option and includes a three-month probationary termination clause. The solicitation does not name explicit set-asides for disadvantaged enterprises. Given the sparse recent activity under this code, business development professionals should monitor whether additional county health departments or state pharmaceutical procurement initiatives adopt it for similar naloxone and emergency-response medical supply buys.